Short Interest in Daré Bioscience, Inc. (NASDAQ:DARE) Expands By 50.9%

Daré Bioscience, Inc. (NASDAQ:DARE) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 86,600 shares, a growth of 50.9% from the December 15th total of 57,400 shares. Based on an average trading volume of 50,200 shares, the short-interest ratio is currently 1.7 days. Approximately 1.0% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Daré Bioscience in a research note on Tuesday, December 17th.

Institutional Trading of Daré Bioscience

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC raised its stake in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the period. Renaissance Technologies LLC owned approximately 9.25% of Daré Bioscience worth $262,000 as of its most recent filing with the SEC. 6.70% of the stock is currently owned by institutional investors and hedge funds.

Daré Bioscience Stock Performance

NASDAQ DARE traded up $0.01 on Friday, reaching $3.34. The company’s stock had a trading volume of 11,893 shares, compared to its average volume of 22,963. Daré Bioscience has a twelve month low of $2.67 and a twelve month high of $7.56. The firm’s 50 day moving average is $3.30 and its two-hundred day moving average is $3.42. The stock has a market cap of $29.06 million, a PE ratio of -5.65 and a beta of 1.28.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.